Quantcast
Last updated on April 19, 2014 at 1:20 EDT

Latest Organofluorides Stories

2013-12-10 08:22:49

New plant in Geismar, Louisiana, will help meet growing global demand for environmentally-friendlier automobile refrigerant with global warming potential of less than 1, a 99.9% improvement over the current refrigerant MORRIS TOWNSHIP, N.J., Dec. 10, 2013 /PRNewswire/ -- Honeywell (NYSE: HON) announced today that investments of approximately $300 million will be made by the company and key suppliers to increase production capacity for HFO-1234yf, a new refrigerant for automobiles...

Scientists Discover Gene That May Predict Response To Antidepressants
2013-12-10 07:53:02

redOrbit Staff & Wire Reports - Your Universe Online Treating depression using selective serotonin reuptake inhibitors (SSRIs) is often a trial-and-error process, but new research appearing in the journal Translational Psychiatry lays the foundation for a new genetic test that could allow doctors to provide patients with a personalized treatment program. Researchers at Tel Aviv University (TAU) explained that SSRIs do not work for everyone, even though they are the most commonly...

2013-12-09 12:24:34

NEW YORK, Dec. 9, 2013 /PRNewswire/ -- As Lipitor lawsuits (http://www.thelipitorlawsuit.com/ ) alleging use of the statin caused patients to develop Type 2 diabetes continue to move forward in U.S. courts, Bernstein Liebhard LLP notes that the Journal of the American Medical Association (JAMA) has published a new editorial that expresses concerns about the possible "statinazation" of the U.S. Its December 2(nd) publication follows the issuance of new guidelines last month by the...

2013-12-08 20:20:38

- ENESTnd data indicate trend for longer overall survival and event-free survival in newly diagnosed Ph+ CML patients on Tasigna versus Gleevec(1) EAST HANOVER, N.J., Dec. 8, 2013 /PRNewswire/ -- Findings from three large, randomized Phase III studies demonstrate the superiority of Tasigna(®) (nilotinib) compared to Gleevec(®) (imatinib mesylate) tablets* at achieving deeper molecular responses across various Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) patient...

2013-12-05 23:23:04

A recent study featured in the latest issue of The Oncologist shows that active smoking greatly diminishes patients’ chances of responding to chemotherapeutic treatment for renal cell carcinoma (RCC). The research team, jointly led by Dr. Michael Carducci from the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD and Dr. Daniel Keizman from the Sackler School of Medicine at Tel Aviv University, conducted a retrospective analysis exploring the association of...

2013-12-05 12:29:57

Manufacturers are Achieving Market Access for Targeted NSCLC Drugs Through Provincial and Municipal Channels in China, According to a New Report from Decision Resources BURLINGTON, Mass., Dec. 5, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of non-small-cell lung cancer (NSCLC), biomarker testing is already widely employed in the China and South Korea markets,...

2013-12-05 08:29:33

INDIANAPOLIS, Dec. 5, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that results from three studies of edivoxetine did not meet the primary study objective of superior efficacy in depression after eight weeks of treatment. When added to a selective serotonin reuptake inhibitor (SSRI), edivoxetine did not separate from placebo on the Montgomery-Asberg Depression Rating Scale (MADRS) in three acute randomized placebo-controlled Phase III studies (LNBM, LNBQ and...

2013-12-05 08:29:22

SOCRATES compares ticagrelor versus aspirin for the prevention of major vascular events in patients with acute ischaemic stroke or transient ischaemic attack THEMIS compares ticagrelor versus placebo for the long-term prevention of major vascular events in patients with Type 2 diabetes at high cardiovascular risk MISSISSAUGA, ON, Dec. 5, 2013 /CNW/ - AstraZeneca has announced plans to conduct two new Phase IIIb clinical studies as part of PARTHENON, the company's largest...

2013-12-04 23:33:38

The Firm is investigating legal claims on behalf of alleged victims of Risperdal and gynecomastia, or male breast growth. New York, New York (PRWEB) December 03, 2013 Hundreds of Risperdal lawsuits (http://www.risperdallawsuitcenter.com/), including many that allege a link between Risperdal and gynecomastia (male breast growth), continue to move forward in a consolidated litigation underway in the Pennsylvania Court of Common Pleas in Philadelphia. According to a Motion filed on November...

2013-12-04 23:27:46

The firm is currently offering Risperdal lawsuit evaluations to those who allege that they suffered from the drug’s alleged side effects. (PRWEB) December 04, 2013 Drug maker Johnson & Johnson has requested that a Pennsylvania state judge keep sealed documents pertaining to results of clinical studies involving antipsychotic medication Risperdal, according to court documents. The Rottenstein Law Group LLP, which represents clients in Risperdal lawsuits, discusses the nature of the...